Austin, United States, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Surgical Staplers Market Size & Growth Analysis: According to SNS Insider, The Surgical Staplers Market was valued at USD 6.41 billion in 2025 and is projected to reach USD 10.87 billion by 2033, growing at a CAGR of 6.87% during the forecast period 2026-2033. The global burden of chronic diseases that require surgical intervention, rising surgical procedure volumes, and the growing acceptance of minimally invasive and laparoscopic surgeries are all f ...

Smith & Nephew plc (NYSE:SNN) is one of the stocks Jim Cramer recently looked at. When a caller inquired about the stock, Cramer was quick to say: They have to, they have to be sold, okay? I just, this group, I do not like. Okay, I just don’t like them because it’s commoditized, alright? I remember I asked my wife… she got a new knee, I said, well, who’d you use? Which one? She goes, it doesn’t matter. And that’s the answer. Pixabay/Public Domain Smith & Nephew plc (NYSE:SNN) manufactures medical tech ...

其核心技术特征包括： 2026年1月15日，英国医疗科技公司 施乐辉（Smith+Nephew） 宣布，已达成协议，将以最高 4.5亿美 元（约合人民币31亿元） 的对价收购美国骨科公司 Integrity Orthopaedics 。 根据公告，交易结构包括： 施乐辉表示，该交易预计于 2026 年内完成，并有望在 2028 年前对集团交易利润率产生正向贡献。 此 次收购也被纳入其 "RISE 2026" 战略框架之下。 # 围绕肩袖修复的技术与市场逻辑 Tendon Seam™：针对高失败率手术场景的修复系统 Integrity Orthopaedics 的核心产品为 Tendon Seam™ 旋转袖修复系统 ，主要用于肩袖（rotator cuff）等软组织 重新固定至骨面的手术。 根据施乐辉在公告中引用的数据， 传统肩袖修复手术的结构性失败率约为 20–40% ，是长期存在的临床痛 点。Tendon Seam™ 的设计目标，正是针对这一问题提升初始固定强度与整体修复稳定性。 2.25 亿美元现金预付款； 未来五年内最高 2.25 亿美元的业绩里程碑付款。 使用 微型锚钉（micro-anchors） ...

Core Viewpoint - Smith+Nephew has completed the acquisition of Integrity Orthopaedics, enhancing its sports medicine shoulder repair business with advanced technologies for rotator cuff repair [1][6]. Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with annual sales of $5.8 billion in 2024 [9]. - The company operates in approximately 100 countries and employs around 17,000 people [9]. Acquisition Details - The acquisition of Integrity Orthopaedics strengthens Smith+Nephew's portfolio in the rotator cuff repair (RCR) market, which sees around 500,000 procedures annually in the US [5]. - Integrity Orthopaedics is known for its Tendon Seam™, a biomechanical RCR system aimed at reducing re-tear rates and improving patient outcomes [2][5]. Product Innovation - Tendon Seam™ features a novel repair stitch configuration with patented microanchors and continuous suture, designed to provide stronger repairs and accelerate patient recovery [3]. - Early clinical experiences indicate lower re-tear rates and shorter procedures compared to traditional methods, with the system receiving 510(k) clearance in 2023 [3][5]. Market Positioning - The Tendon Seam™ technology complements Smith+Nephew's existing REGENETEN Bioinductive Implant, creating a unique and differentiated RCR portfolio that combines biomechanical repair and biological augmentation [6]. - The company aims to leverage its commercial channels in the US to accelerate the adoption of Tendon Seam™ while building evidence for global adoption [7].

Company Overview - Smith + Nephew (SNN) has acquired Integrity Orthopaedics, enhancing its Sports Medicine portfolio with the Tendon Seam rotator cuff repair system, aimed at reducing re-tear rates in the shoulder repair market [1][8] - The acquisition is valued at $225 million upfront, with an additional $225 million contingent on performance milestones over five years [7][9] Market Position and Strategy - This acquisition strengthens SNN's leadership in shoulder repair by complementing its existing biological and mechanical solutions, positioning the company as a full-spectrum shoulder solutions provider [2][4] - The rotator cuff repair (RCR) market is significant, with approximately 500,000 procedures performed annually in the U.S., representing an estimated $875 million market opportunity [10] Financial Impact - The deal is expected to be margin accretive by 2028, funded through existing cash facilities, which will maintain leverage below the company's target of 2x EBITDA [9][8] - SNN's current market capitalization stands at $13.89 billion [6] Product Integration and Innovation - The Tendon Seam system is designed to address high structural failure rates associated with traditional techniques, potentially leading to lower re-tear rates and improved patient outcomes [11] - This acquisition complements SNN's existing products, including REGENETEN, Q-FIX, and AETOS, broadening its shoulder portfolio and enhancing cross-selling opportunities [12] Industry Outlook - The global orthopedic trauma devices market is projected to grow from $18.5 billion in 2022 to approximately $38.2 billion by 2030, at a CAGR of about 9.5% [13] - The growth is driven by increasing road accidents and an aging population, boosting demand for advanced trauma care solutions [14] Strategic Initiatives - SNN's RISE strategy aims for faster revenue growth, higher profitability, and improved free cash flow by 2028, with a revised trading profit margin guidance of at least 19.5% and free cash flow of around $800 million for 2025 [15]

Core Viewpoint - British medical products maker Smith & Nephew is set to acquire U.S.-based Integrity Orthopaedics in a deal potentially valued at up to $450 million [1] Company Summary - Smith & Nephew is a British company specializing in medical products [1] - The acquisition of Integrity Orthopaedics represents a strategic move to enhance Smith & Nephew's portfolio in the orthopedic sector [1] Financial Summary - The deal could be valued at up to $450 million, indicating a significant investment by Smith & Nephew in expanding its market presence [1]

Core Insights - Smith & Nephew (SNN) has shown a mixed but generally positive performance over the past year, although it is still underperforming in the major joints segment [1] Group 1: Company Performance - The company is facing challenges in the major joints market, indicating potential areas for improvement [1] - Competition in the industry remains a concern for Smith & Nephew, which may impact its market position [1]

Core Insights - Smith & Nephew (SNN) has shown a mixed but generally positive performance over the past year, although it is not performing as well as desired in the major joints segment [1] Group 1: Company Performance - The overall picture for Smith & Nephew is positive, but there are concerns regarding its performance in major joints [1] - Competition in the industry may be impacting the company's performance [1]

Summary of Smith & Nephew Capital Markets Day Company Overview - **Company**: Smith & Nephew (NYSE: SNN) - **Event**: 2025 Capital Markets Day held on December 11, 2025 - **Industry**: Medical Technology Key Messages and Strategies - **12-Point Plan**: Actions taken under this plan have strengthened the business significantly over the past three years, setting a foundation for future growth [2][3] - **New Strategy - RISE**: Aims to accelerate growth and improve returns, targeting 6%-7% organic growth and 9%-10% trading profit over the next three years [3][11] - **Financial Goals**: Expected to generate $1 billion in free cash flow by 2028 and achieve a 12%-13% Return on Invested Capital (ROIC) [3] Market Position and Growth Opportunities - **Total Addressable Market**: $50 billion, growing at approximately 6% [5] - **Sports Medicine Market**: $7 billion, with Smith & Nephew as the second-largest player [5] - **Wound Care Market**: $13 billion, also with a significant position in biologics and single-use negative pressure wound therapy [5][6] - **Orthopedics Market**: Smaller position but with differentiated technology for future growth [6] Product Innovations and Launches - **New Product Launches**: Over 75 new products introduced in the last five years, with more expected in the next 18 months [11][12] - **ALLEVYN Dressing**: Launched to prevent pressure injuries, showing a 94% effectiveness rate [16] - **PICO Device**: A single-use negative pressure wound therapy device that reduces surgical site complications by up to 63% [22][41] Operational Improvements - **Manufacturing Efficiency**: Closed five facilities to better match demand and improved operational efficiency at the Memphis site [8][10] - **Inventory Management**: Positive steps taken to align supply and demand, with further margin improvements anticipated [10] Leadership and Team Strength - **Executive Team**: Composed of industry leaders with extensive experience, positioned to drive the company's strategy forward [6][8] Financial Projections and Market Share Goals - **Patient Reach**: Targeting to increase the number of patients treated from 15 million to 20 million by 2028 [11] - **Market Leadership**: Aiming to transition from category leader to market leader in sports and wound care [13] Challenges and Areas for Improvement - **Product Gaps**: Some areas did not meet growth ambitions due to shifting market trends [9] - **Inventory Alignment**: Currently about a year behind in inventory reduction goals [10] Conclusion - Smith & Nephew is positioned for significant growth through its RISE strategy, innovative product offerings, and operational improvements, with a strong focus on enhancing patient outcomes and expanding market share in the medical technology sector [3][11][12]

Core Viewpoint - Smith & Nephew is hosting its London Capital Markets Day 2025, marking a significant event for the company and its investors [1][2] Group 1: Event Overview - The event is the first of two taking place this week, indicating a structured approach to investor engagement [1] - Emily Heaven, the Head of Investor Relations, emphasizes her transition from investor to company representative, highlighting a commitment to investor relations [1] Group 2: Logistics and Agenda - The event includes logistical details such as fire safety instructions and scheduled coffee breaks, ensuring a well-organized experience for attendees [2] - Attendees are encouraged to explore product fairs, suggesting a focus on showcasing company offerings [2]